Prime

Type your tag names separated by a space and hit enter

Magnesium in CKD: more than a calcification inhibitor?

Abstract

Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Pauwelsstr. 30, 52057, Aachen, Germany, juergen.floege@rwth-aachen.de.

    Source

    Journal of nephrology 28:3 2015 Jun pg 269-77

    MeSH

    Animals
    Bone and Bones
    Comorbidity
    Depression
    Diabetes Mellitus
    Dietary Supplements
    Fatigue
    Health Status
    Humans
    Hypertension
    Kidney
    Magnesium
    Renal Insufficiency, Chronic
    Risk Factors
    Vascular Calcification

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    25227765

    Citation

    TY - JOUR T1 - Magnesium in CKD: more than a calcification inhibitor? A1 - Floege,Jürgen, Y1 - 2014/09/17/ PY - 2014/07/22/received PY - 2014/09/02/accepted PY - 2014/9/18/entrez PY - 2014/9/18/pubmed PY - 2016/2/18/medline SP - 269 EP - 77 JF - Journal of nephrology JO - J. Nephrol. VL - 28 IS - 3 N2 - Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context. SN - 1724-6059 UR - https://www.unboundmedicine.com/medline/citation/25227765/full_citation L2 - https://dx.doi.org/10.1007/s40620-014-0140-6 ER -